Actavis acquires pain drug from King Pharmaceuticals
Kadian which is an extended release morphine sulfate product is the first originator brand product to be marketed by Actavis US. The company anticipates marketing Kadian only in
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.